Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20692404 | 1.00 | HTR2C (0.38) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL20692405 | 0.90 | HTR2C (0.39) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL20692086 | 0.84 | HTR2C (0.35) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL18416938 | 0.83 | SSTR4 (0.40) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL20680976 | 0.83 | CA2 (0.41) | RIPK1KMT2ACA2ALDH1A1HPGD | |
| SCHEMBL20692403 | 0.81 | SCN3A (0.38) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL20681015 | 0.80 | CA2 (0.50) | CA2CA12CA1CA9CA14 | |
| SCHEMBL506105 | 0.80 | RIPK1 (0.40) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL506457 | 0.79 | GRM2 (0.40) | HTR2CSLC6A4GRM2GLSRIPK1 | |
| SCHEMBL22012064 | 0.78 | HTR2C (0.36) | HTR2CSLC6A4GRM2GLSRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| EP-4349820-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-3658539-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-12-28 | — | — | US | disclosed |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-08-15 | — | — | US | disclosed |
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-03-02 | — | — | US | disclosed |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062815-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HTR2C 3462/4885SLC6A4 2344/4885GRM2 2380/4885 |
| US-20230051589-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HTR2C 3684/4885SLC6A4 2720/4885GRM2 2687/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | HTR2C 3462/4885SLC6A4 2344/4885GRM2 2380/4885 |
| US-11724992-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | HTR2C 3462/4885SLC6A4 2344/4885GRM2 2380/4885 |
| US-20230416211-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | HTR2C 3462/4885SLC6A4 2344/4885GRM2 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.